// App-Quantinova.ai

3753 : Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Meir Wetzler

  • Jeffrey H. Lipton

  • Michele Baccarani

  • Dan Douer

  • Adam Craig

  • Hagop M. Kantarjian

  • Luke Akard

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • United States

  • Canada

  • Italy

Companies

  • Teva Pharmaceutical

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Hypercalcaemia

  • Neutropenia

  • Anemia

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Omacetaxine mepesuccinate

  • Hydroxyurea

  • Hydroxycarbamide

  • Cytarabine liposomal

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved